Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | -0.06% | 53.94 | 0.9% | $1407.22m | |
| JNJ | Johnson & Johnson | -0.05% | 179.46 | 0.7% | $1295.87m | |
| BMY | Bristol-Myers Squibb Co. | 0.00% | 77.59 | 1.0% | $1212.16m | |
| MRK | Merck & Co., Inc. | -0.01% | 92.31 | 0.7% | $1166.90m | |
| ABBV | AbbVie, Inc. | 0.20% | 150.86 | 1.9% | $1102.49m | |
| LLY | Eli Lilly & Co. | -0.01% | 313.46 | 1.1% | $967.22m | |
| BHVN | Biohaven Pharmaceutical Holding Co. Ltd. | -0.14% | 142.98 | 0.0% | $491.89m | |
| AZN | AstraZeneca Plc | -0.11% | 66.63 | 1.0% | $490.99m | |
| NVS | Novartis AG | 0.00% | 91.26 | 0.2% | $259.85m | |
| GSK | GlaxoSmithKline Plc | 0.01% | 44.42 | 0.2% | $257.59m | |
| VERU | Veru, Inc. | 0.40% | 12.69 | 0.0% | $254.71m | |
| HZNP | Horizon Therapeutics Plc | 0.00% | 90.59 | 5.4% | $196.03m | |
| SGEN | Seagen Inc. | 0.00% | 138.46 | 5.7% | $185.67m | |
| NVO | Novo Nordisk A/S | -0.02% | 106.60 | 0.1% | $182.86m | |
| VTRS | Viatris, Inc. | 0.00% | 12.01 | 0.0% | $165.27m |
Company Profile
Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.